Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings results on Monday. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03), FiscalAI reports. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The company had revenue of $890.37 million during the quarter, compared to the consensus estimate of $893.13 million. During the same period in the previous year, the firm posted $0.06 EPS. The business’s quarterly revenue was up 48.6% compared to the same quarter last year.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue grew 49% year over year to $890 million, accelerating for a second consecutive quarter; domestic revenue growth also improved to 21%. Adjusted EBITDA was $82 million, and the company generated $26 million of free cash flow.
• Subscribers fell by 100,000 sequentially to 2.8 million, which management attributed largely to deliberately lower U.S. weight-loss marketing and international brand migrations. The company expects subscriber headwinds to continue in Q4, with growth recovery anticipated after marketing ramps up in Q1.
• Hims & Hers lowered its 2026 Adjusted EBITDA guidance to $257 million–$277 million and expects Q4 revenue growth to slow to 42%–45%. Gross margin declined about seven percentage points sequentially to 57%, primarily due to a greater mix of lower-margin branded weight-loss products internationally.
• The company is expanding weight-loss options through Lilly and Novo partnerships, and raised its 2026 international revenue expectation to at least $650 million. Management says the AI-native experience reached 70% of weight-loss subscribers and users send four times as many messages, though these investments and broader international marketing may weigh on near-term results.
• Hims & Hers plans to launch Peptides+ later this month and recently expanded injectable and oral testosterone offerings, using its own pharmacy and lab infrastructure. Peptide revenue is not expected to be material in Q4, and some planned products depend on regulatory clarity.

Hims & Hers Health Stock Up 9.0%

Shares of NYSE HIMS opened at $20.86 on Thursday. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.87 and a current ratio of 0.92. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $40.99. The stock has a market capitalization of $4.87 billion, a P/E ratio of -25.13 and a beta of 2.53. The stock’s fifty day moving average is $27.95 and its 200 day moving average is $26.80.

Recent Hims & Hers Health Headlines

Investors following HIMS have been watching these headlines:

• Neutral Sentiment: The company appointed Andrew Huberman to its board and has discussed offering peptides, which could support its growth strategy but do not resolve near-term concerns around margins, demand or regulation. Article: Hims & Hers Announces Andrew Huberman as Director
• Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, and fourth-quarter revenue guidance of $875 million–$895 million came in well below analysts’ expectations. The cut adds to concerns about the company’s earnings trajectory. Article: Hims & Hers Cuts 2026 Earnings Outlook
• Negative Sentiment: Five states have joined an FTC lawsuit alleging unlawful privacy practices, creating additional legal and reputational risk. Analysts also lowered price targets, including Morgan Stanley, which maintained an equal-weight rating while cutting its target from $28 to $25. Article: Five US States Join FTC Suit Against Hims & Hers

Analyst Ratings Changes

A number of research analysts have commented on the company. Jefferies Financial Group decreased their price objective on Hims & Hers Health from $31.00 to $24.00 and set a “hold” rating on the stock in a report on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research note on Wednesday, November 4th. Needham & Company LLC lowered their price target on shares of Hims & Hers Health from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Bank of America raised their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, Deutsche Bank lifted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $31.53.

Insiders Place Their Bets

In related news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This trade represents a 2.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the sale, the chief financial officer owned 234,527 shares in the company, valued at approximately $6,965,451.90. This represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 133,905 shares of company stock worth $3,826,977 over the last three months. Insiders own 11.76% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.